Discover how to turn creative ideas into stunning visuals with invideo AI, followed by a detailed step-by-step tutorial on making your own combination lock from metal. This video explores both the ...

Private equity firm Cinven is considering a sale of German software company think-cell, which could be valued at as much as €3 billion ($3.5 billion) in a deal, according to people familiar with the ...

A Wake Forest woman tried and over and over again to get Verizon to cancel her husband's phone service to no avail. She finally contacted 5 On Your Side and, within a week, the matter was resolved. A ...

The FDA approved lurbinectedin (Zepzelca) plus either atezolizumab (Tecentriq) or atezolizumab and hyaluronidase (Tecentriq Hybreza) as first-line maintenance therapy for extensive-stage small cell ...

An FDA approval is setting a new benchmark for future treatment for first-line small cell lung cancer. The FDA has greenlighted Jazz Pharmaceuticals’ Zepzelca, used in combination with Roche’s ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved the combination of lurbinectedin and atezolizumab as first-line maintenance treatment for ...

Lurbinectedin, combined with atezolizumab or atezolizumab and hyaluronidase, is FDA-approved for ES-SCLC patients without disease progression post-induction therapy. Lurbinectedin is administered ...

An observational study was conducted across three Spanish hospitals to compare two glucocorticoid regimens in treating 151 patients newly diagnosed with giant cell arteritis (mean age, 74.6 years; 71% ...

Shane Larkin: So I think the combination of like the flair, the excitement, the talent, the IQ, all of it, and a 23-year-old kid that is only going to continue to grow and become better. I mean, no ...

Below, an edit of the best options well regarded by three board-certified dermatologists who reveal their favorite moisturizers for combination skin, from gel-creams to lightweight lotions. Each one ...

All five patients in a trial with recurrent glioblastoma given a combination of ImmunityBio's (NASDAQ:IBRX) natural killer (NK) cell therapy Anktiva and Novocure's (NASDAQ:NVCR) Optune Gio Tumor ...